TrivarX Limited
0.01
USD
+0.00
(-12.35%)
ISIN
AU0000300196
Return %
Stock
S&P 500
1Y
-70.84
14.39
3Y
-38.26
81.42
5Y
-94.93
68.62
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- Danielle Meyrick
- Full Time Employees
- 6
- Sector
- Technology services
- Industry
- Packaged software
- Address
- Suite 1.01, 117 Camberwell Road Mt. Lawley VIC Australia 3123
- IPO Date
- Dec 1, 2000
- Website
- trivarx.com
- Similar Companies
- Business
- TrivarX Limited (TRI.AX) engages in the development and commercialization of AI-driven, scientifically based devices and software for screening and diagnosing behavioral health conditions, with a focus on sleep and autonomic nervous system metrics. The company operates primarily through its software-as-a-service platform and related medical devices designed to analyze physiological signals for mental health assessment. TrivarX maintains a two-country footprint, with operational presence in Australia and the United States, and maintains a corporate structure centered on research, development, and commercial deployment of its health technology offerings. The company was founded in 2010 and is headquartered in Frankfurt am Main, Germany, positioning itself to serve global markets through strategic partnerships and regulatory-compliant product launches. Core capabilities include proprietary algorithms for spectral analyses of sleep architecture and heart rate variability, enabling products that identify depression and other mental health conditions from physiological data. Primary product categories comprise AI-powered diagnostic devices, cloud-based data analytics platforms, and subscription-based access to clinical decision-support tools for healthcare providers and enterprise clients. TrivarX’s ecosystem emphasizes clinical research-backed technology, with ongoing collaboration initiatives aimed at expanding validation studies, refining diagnostic accuracy, and broadening application across behavioral health care settings. Recent corporate activity highlights include strategic partnerships with healthcare institutions and technology firms to scale deployment in target markets, ongoing development of enhanced SaaS offerings, and expanded commercial outreach in the US and Australian markets. The company maintains a focus on enterprise and clinical customers, including healthcare providers, research organizations, and corporate health programs, as it scales its AI-driven screening solutions globally.